immune system
• following treatment with a CD3 or CD28 antibody, T cell proliferation is attenuated
• in vitro, CD4+ cell proliferation is severely attenuated while CD8+ proliferation is only moderately affected
|
• fewer CD4+ single positive cells are present compared to in wild-type mice
|
• more CD8+ single positive cells are present compared to in wild-type mice
|
• IgG1 levels are decreased
• following TNP-CGG treatment, IgG1 levels are lower than in control mice
|
• following TNP-CGG treatment, IgG2a levels are lower than in control mice
|
• IgM levels are lower than in wild-type mice
• following TNP-Ficoll treatment, IgM levels are reduced by greater than 80% compared wild-type mice
|
• B cell proliferation in response to IgM and CD40 is reduced
|
• absolute numbers are decreased by 63% compared to wild-type
|
• lymphoid organs including thymus, spleen, peripheral lymph nodes and Peyer's patches are reduced in total cell numbers by about 30 to 60%
|
• humoral response to TNP-Ficoll and TNP-CGG is attenuated
|
• in vitro, gamma-interferon production by CD3 antibody stimulated mutant T cells was impaired
|
• in vitro, IL-10 production by CD3 antibody stimulated mutant T cells was impaired
|
• in vitro, IL-2 production by CD3 antibody stimulated mutant T cells was impaired
|
• in vitro, IL-4 production by CD3 antibody stimulated mutant T cells was impaired
|
• in vitro, TNF production by CD3 antibody stimulated mutant T cells was impaired
|
• semi-identical allografts have increased survival, with half survive more than 60 days, compared to in wild-type
|
hematopoietic system
• following treatment with a CD3 or CD28 antibody, T cell proliferation is attenuated
• in vitro, CD4+ cell proliferation is severely attenuated while CD8+ proliferation is only moderately affected
|
• absolute numbers are decreased by 63% compared to wild-type
|
• fewer CD4+ single positive cells are present compared to in wild-type mice
|
• more CD8+ single positive cells are present compared to in wild-type mice
|
• IgG1 levels are decreased
• following TNP-CGG treatment, IgG1 levels are lower than in control mice
|
• following TNP-CGG treatment, IgG2a levels are lower than in control mice
|
• IgM levels are lower than in wild-type mice
• following TNP-Ficoll treatment, IgM levels are reduced by greater than 80% compared wild-type mice
|
• B cell proliferation in response to IgM and CD40 is reduced
|
cellular
• following treatment with a CD3 or CD28 antibody, T cell proliferation is attenuated
• in vitro, CD4+ cell proliferation is severely attenuated while CD8+ proliferation is only moderately affected
|